Hemodynamic Support With the Impella 5.5 Acute Mechanical Circulatory Support Device

Area of Science:

• Cardiology
• Medical Devices
• Hemodynamics

Background:

• The Impella 5.5 is increasingly utilized for advanced heart failure management.
• Clinical trial evidence for its efficacy is limited, necessitating real-world outcome data.

Purpose of the Study:

• To evaluate the real-world outcomes and hemodynamic effects of the Impella 5.5 in patients requiring circulatory support.
• To assess the Impella 5.5's role as a bridge to recovery, durable left ventricular assist device (LVAD), or heart transplant.

Main Methods:

• A retrospective analysis of 150 consecutive patients receiving Impella 5.5 support at a high-volume center.
• Primary outcome: composite of recovery, durable LVAD, or heart transplant versus 90-day mortality.
• Secondary outcomes: hemodynamic trends and need for upgrade to veno-arterial extracorporeal membrane oxygenation (VA-ECMO).

Main Results:

• The composite endpoint (recovery, LVAD, or transplant) occurred in 59.3% of patients, with 18.8% mortality at 90 days.
• Impella 5.5 support led to significant decreases in pulmonary artery diastolic pressure (PADP), estimated pulmonary arterial elastance (Ea), and vasoactive-inotropic score (VIS).
• Patients requiring VA-ECMO upgrade showed higher baseline right atrial pressure (RAP), PADP, and lower pulmonary artery pulsatility index (PAPi), indicating potential right ventricle dysfunction.

Conclusions:

• The Impella 5.5 demonstrates effectiveness in improving hemodynamics and bridging patients to recovery or heart replacement therapies.
• Hemodynamic monitoring is crucial for managing patients with Impella 5.5, particularly those with concurrent right ventricle dysfunction.
• Real-world data support the Impella 5.5's role in managing advanced heart failure.